What Is Senolytics

Senolytics are a class of compounds designed to selectively induce death in senescent cells, which are damaged or aged cells that have permanently exited the cell cycle but remain metabolically active. These "zombie" cells resist apoptosis (programmed cell death), accumulate in tissues over a lifetime, and secrete a mixture of inflammatory molecules collectively known as the senescence-associated secretory phenotype (SASP). By clearing these cells, senolytics aim to reduce the chronic low-grade inflammation and tissue dysfunction associated with aging.

Cellular senescence is one of the nine hallmarks of aging proposed in the scientific literature. A small number of senescent cells can produce outsized effects because the SASP they release acts on surrounding healthy cells, promoting further senescence, disrupting tissue repair, and fueling systemic inflammation. This cascade has been implicated in conditions ranging from osteoarthritis and pulmonary fibrosis to cardiovascular disease and cognitive decline.

For longevity, the accumulation of senescent cells represents a form of biological debt. The immune system normally clears many senescent cells through surveillance mechanisms involving natural killer cells and macrophages, but this process becomes less efficient with age. When clearance fails to keep pace with accumulation, tissue function declines. Senolytics address this imbalance directly by targeting the pro-survival pathways that allow senescent cells to persist, offering a potential intervention at the level of a root biological mechanism rather than a downstream symptom.

Senescent cells survive by upregulating anti-apoptotic pathways, essentially strengthening their internal defenses against programmed death. Key survival networks include the BCL-2/BCL-xL family of proteins, PI3K/AKT signaling, p53/p21 pathways, and various tyrosine kinase receptors. These pathways function like a life raft for cells that would otherwise be cleared. Senolytics work by disabling specific components of this survival machinery, tipping senescent cells past the threshold where they can no longer resist apoptosis.

Different senolytic compounds target different survival nodes. Dasatinib, originally developed as a leukemia treatment, inhibits multiple tyrosine kinases that senescent cells depend on, including ephrin receptors and Src family kinases. Quercetin inhibits PI3K, serpins, and BCL-xL. Used together, they cover a broader range of senescent cell types, since different tissues harbor senescent cells with different survival dependencies. Fisetin appears to act through overlapping but distinct mechanisms, including modulation of the PI3K/AKT/mTOR axis. Navitoclax directly inhibits BCL-2 and BCL-xL proteins, though its platelet toxicity limits clinical use.

The intermittent dosing strategy used in senolytic protocols reflects the biology of the target. Because senescent cells accumulate gradually over weeks and months, a brief exposure to the senolytic compound can trigger apoptosis in the existing burden, after which the treatment is discontinued until the next cycle. This "hit and run" approach reduces continuous drug exposure and theoretically minimizes side effects. Following senolytic clearance, the surrounding tissue microenvironment may improve as SASP-driven inflammation subsides, potentially allowing progenitor and stem cells to resume normal repair functions.

Senolytic compounds come in several distinct forms depending on the agent. Dasatinib is available only as a prescription oral tablet (marketed under the brand Sprycel for cancer indications) and is used off-label in longevity contexts. Quercetin is widely available as an oral supplement in capsule and powder forms, with various formulations including phytosomal and liposomal versions designed to improve its otherwise low bioavailability. Fisetin is sold as an oral supplement, typically in capsule form, with some products incorporating lipid-based delivery systems to enhance absorption.

The oral route is standard for all current senolytic protocols. No injectable or topical senolytic formulations are in common clinical use for aging applications, though research-stage approaches including nanoparticle delivery systems and prodrug designs are being developed to target senescent cells more selectively and reduce off-target effects. For the supplement-based senolytics (quercetin and fisetin), bioavailability is a meaningful consideration, since both are flavonoids with limited intestinal absorption in their native forms. Taking them with a fat-containing meal or choosing enhanced-absorption formulations may improve uptake.

Senolytic dosing differs fundamentally from typical supplement use. Rather than daily consumption, the standard research approach uses intermittent high-dose courses. In human pilot studies, dasatinib has been administered at approximately 100 mg per day and quercetin at approximately 1000 mg per day, taken together for two or three consecutive days per cycle. Cycles are repeated at intervals ranging from every two weeks to every few months, depending on the protocol and clinical context.

Fisetin dosing in human trials has used approximately 20 mg per kilogram of body weight per day over two consecutive days, which is substantially higher than the doses found in typical fisetin supplements (100 to 500 mg per capsule). This distinction matters: the doses used for senolytic effect are not the same as the doses commonly marketed for general antioxidant support. No consensus exists on optimal cycle frequency, duration of treatment courses, or total number of cycles. Individual variation in senescent cell burden, immune function, and metabolic status likely means that a one-size-fits-all protocol is insufficient, but the tools to personalize dosing do not yet exist in clinical practice.

For quercetin supplements, look for products that disclose the specific form used (quercetin dihydrate, quercetin anhydrous, or quercetin phytosome) and provide third-party testing certificates for identity, potency, and contaminant screening (heavy metals, microbials, pesticides). Phytosomal quercetin (bound to phospholipids) has demonstrated meaningfully higher bioavailability in pharmacokinetic studies compared to standard quercetin powder. Products carrying NSF International, USP, or Informed Sport certification offer an additional layer of manufacturing quality assurance.

For fisetin, the market is less mature and quality variation is wider. Because fisetin is typically extracted from plant sources (Rhus succedanea or Cotinus coggygria), purity can vary considerably between manufacturers. Look for products that specify purity percentage (98% or higher is standard for research-grade material) and provide certificates of analysis. Synthetic fisetin is also available and may offer more consistent purity. Regardless of the compound, any product intended for senolytic-level dosing should ideally come from a manufacturer that follows current Good Manufacturing Practices (cGMP) and can provide batch-specific testing data.

The foundational animal research on senolytics has been extensive and internally consistent. Studies in aged mice using dasatinib plus quercetin, fisetin, or navitoclax have demonstrated reductions in senescent cell markers, decreased inflammatory cytokine levels, improved physical function (including treadmill endurance and grip strength), and in some cases extended median lifespan. Transplanting senescent cells into young mice accelerates functional decline, and treating those mice with senolytics reverses the effect, providing causal evidence for the role of senescent cells in aging phenotypes.

Human evidence remains early-stage. Small pilot trials have tested dasatinib plus quercetin in patients with idiopathic pulmonary fibrosis, diabetic kidney disease, and Alzheimer's disease, with preliminary signals suggesting reductions in senescent cell markers and SASP factors. A larger trial of fisetin in older adults (the AFFIRM trial) has been conducted, though results from definitive efficacy endpoints are still being analyzed and published. No large, long-term randomized controlled trial has yet demonstrated that senolytics improve hard clinical outcomes (disease incidence, mortality, or validated measures of biological age) in humans. The translation gap between mouse models and human aging remains significant, and the field is still working to identify reliable biomarkers for measuring senolytic efficacy in living people.

Dasatinib carries known pharmaceutical side effects including gastrointestinal disturbance, fluid retention, cytopenia (low blood cell counts), and potential cardiac effects; it should only be used under medical supervision. Quercetin and fisetin are generally well tolerated at supplemental doses, but the higher doses used in senolytic protocols have not been evaluated for long-term safety. There is a theoretical concern that excessive senescent cell clearance could impair wound healing or tumor suppression, since senescence serves as a natural brake on damaged cells that might otherwise become cancerous. The intermittent dosing approach is designed partly to mitigate this risk. Individuals with active cancer, compromised immune function, or those on anticoagulant or antiplatelet medications should exercise particular caution. The absence of validated biomarkers to guide dosing frequency means that current protocols are based largely on extrapolation from animal data and clinical intuition rather than precision dosing.